Phase 3 ADHD Trial, Recruiting NCT04704687 Sponsor: Centre Hospitalier Universitaire, Amiens Condition: ADHD
Back to Adhd

Phase 3 ADHD Trial, Recruiting

NCT04704687
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children (boys or girls) aged 7 to 14 years old who are able to participate and cooperate with the study requirements
  • A parent or legal guardian must agree to take part and sign a consent form, and the child may also need to sign an agreement form depending on their age and understanding
  • The child must have been diagnosed with ADHD (combined type) based on specific assessment tools used by a doctor
  • The child must have a high enough ADHD symptom score (at least 32) on a standard rating scale at the first visit
  • The child must have a minimum severity rating of 4 on a clinical scale at the first visit (confirm with trial site)
  • The child must have an age-appropriate level of intelligence, measured by a standard IQ test (full IQ score above 80)
  • Children who previously tried stimulant medication but stopped due to side effects may be eligible, as long as they have not taken the medication for at least 7 days before joining

Who may not be able to join:

  • Children who have a neurological condition such as epilepsy, cerebral palsy, or lasting effects from a brain injury
  • Children who have certain other mental health conditions, such as autism, severe OCD, mood disorders, bipolar disorder, psychosis, conduct disorder, or substance misuse
  • Children who are currently taking stimulant medications, other psychiatric medications, antidepressants, sleeping tablets, melatonin, or benzodiazepines — or children whose ADHD did not improve with stimulant medication in the past
  • Children who have a serious sleep disorder
  • Children for whom the study treatment (a type of mild brain stimulation called tDCS) is not considered safe (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: (33)3 22 08 76 70

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Centre Hospitalier Universitaire, Amiens
Registry
ClinicalTrials.gov
Start date
8 January 2021
Est. completion
1 August 2025

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Variation of ADHD-RS(ADHD Rating Scale-IV) between both arms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov